<DOC>
	<DOC>NCT00506051</DOC>
	<brief_summary>The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.</brief_summary>
	<brief_title>ZD6474(Vandetanib) + Alimta Combo Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Confirmed advanced or metastatic nonsmall cell lung cancer Failure of firstline chemotherapy 1 or more measurable lesion by RECIST Previous chemotherapy or radiotherapy within 4 weeks Significant cardiac events, arrythmias or other cardiac conditions Unacceptable laboratory measurements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>alimta</keyword>
	<keyword>vandetanib</keyword>
	<keyword>phase 1</keyword>
</DOC>